Soleno Therapeutics Inc. News Releases http://investors.soleno.life/ Soleno Therapeutics Inc. News Releases en Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-appointment-veteran-industry REDWOOD CITY, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the appointment of Birgitte Volck , M.D., Ph.D., a veteran Wed, 12 Jun 2019 08:00:00 -0400 Soleno Therapeutics Inc. News Releases 9516 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-provides-corporate-update-and-reports-3 REDWOOD CITY, Calif. , May 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three Mon, 13 May 2019 08:00:00 -0400 Soleno Therapeutics Inc. News Releases 9491 Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-appointment-industry-veteran-gwen REDWOOD CITY, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Gwen A. Mon, 29 Apr 2019 08:00:00 -0400 Soleno Therapeutics Inc. News Releases 9466 Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-present-2019-hc-wainwright-global-life REDWOOD CITY, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will Wed, 03 Apr 2019 08:00:00 -0400 Soleno Therapeutics Inc. News Releases 9401 Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-participate-roth-battle-nash-thrones-spring REDWOOD CITY, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will Mon, 25 Mar 2019 08:00:00 -0400 Soleno Therapeutics Inc. News Releases 9391 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-provides-corporate-update-and-reports-2 REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the Mon, 18 Mar 2019 08:00:00 -0400 Soleno Therapeutics Inc. News Releases 9361 Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-positive-outcome-planned-data REDWOOD CITY, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has recommended the Thu, 14 Mar 2019 17:32:00 -0400 Soleno Therapeutics Inc. News Releases 9336 Soleno Therapeutics to Participate in Two Upcoming Investor Conferences http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-participate-two-upcoming-investor REDWOOD CITY, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will Mon, 11 Mar 2019 12:05:00 -0400 Soleno Therapeutics Inc. News Releases 9331 Soleno Therapeutics Announces $16.5 Million Private Placement http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-165-million-private-placement Financing Led by Abingworth; Andrew Sinclair , Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. Wed, 19 Dec 2018 16:01:00 -0500 Soleno Therapeutics Inc. News Releases 9231 Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018 http://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-presents-clinical-fat-loss-data-dccr-obesity DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome REDWOOD CITY, Calif. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the Thu, 15 Nov 2018 08:05:00 -0500 Soleno Therapeutics Inc. News Releases 9216